JO3713B1 - أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت - Google Patents

أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت

Info

Publication number
JO3713B1
JO3713B1 JOP/2014/0088A JOP20140088A JO3713B1 JO 3713 B1 JO3713 B1 JO 3713B1 JO P20140088 A JOP20140088 A JO P20140088A JO 3713 B1 JO3713 B1 JO 3713B1
Authority
JO
Jordan
Prior art keywords
quinuclidin
thiazol
propan
fluorophenyl
carbamate
Prior art date
Application number
JOP/2014/0088A
Other languages
English (en)
Inventor
Zhao Jin
Siegel Craig
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50543351&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3713(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of JO3713B1 publication Critical patent/JO3713B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups

Abstract

<span dir="RTL">يتعلق الاختراع الحالي بصور جديدة من ملح (</span>S<span dir="RTL">)-كينيوكليدين-3-يل(2-2-(4-فلوروفينيل)ثيازول-4-يل) بروبان-2-يل) كربامات مفيدة كمثبط لإنزيم جلوكوزيل سيراميد سينثاز (</span>GCS<span dir="RTL">) و لعلاج أمراض الأيض، مثل أمراض تخزين الجسيم الحال، سواء بمفرده أو بالترافق مع معالجة بالتعويض عن الإنزيمات، و لعلاج السرطان.</span>
JOP/2014/0088A 2013-03-15 2014-03-11 أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت JO3713B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361791706P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
JO3713B1 true JO3713B1 (ar) 2021-01-31

Family

ID=50543351

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0088A JO3713B1 (ar) 2013-03-15 2014-03-11 أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت

Country Status (34)

Country Link
US (1) US9518049B2 (ar)
EP (1) EP2970250B1 (ar)
JP (1) JP6438455B2 (ar)
KR (1) KR102302064B1 (ar)
CN (1) CN105189490A (ar)
AR (1) AR095435A1 (ar)
AU (1) AU2014240028B2 (ar)
BR (1) BR112015022907B1 (ar)
CA (1) CA2906691A1 (ar)
CL (1) CL2015002701A1 (ar)
DK (1) DK2970250T3 (ar)
EA (1) EA037527B1 (ar)
ES (1) ES2872326T3 (ar)
HK (1) HK1214821A1 (ar)
HR (1) HRP20210692T1 (ar)
HU (1) HUE054349T2 (ar)
IL (1) IL241229B (ar)
JO (1) JO3713B1 (ar)
LT (1) LT2970250T (ar)
MA (1) MA38488A1 (ar)
MX (1) MX370178B (ar)
MY (1) MY181766A (ar)
PH (1) PH12015502021A1 (ar)
PL (1) PL2970250T3 (ar)
PT (1) PT2970250T (ar)
RS (1) RS61852B1 (ar)
SA (1) SA515361078B1 (ar)
SG (1) SG11201507054YA (ar)
SI (1) SI2970250T1 (ar)
TN (1) TN2015000427A1 (ar)
TW (1) TWI713438B (ar)
UY (1) UY35439A (ar)
WO (1) WO2014152215A1 (ar)
ZA (1) ZA201506602B (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201804952QA (en) * 2013-12-11 2018-07-30 Genzyme Corp Glucosylceramide synthase inhibitors
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
JP2022519131A (ja) 2019-02-04 2022-03-18 ジェンザイム・コーポレーション グルコシルセラミドシンターゼ（ｇｃｓ）阻害剤を使用した繊毛病の処置
AU2021215396A1 (en) * 2020-02-03 2022-09-29 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
AU2021311131A1 (en) 2020-07-24 2023-03-23 Genzyme Corporation Pharmaceutical compositions comprising venglustat
WO2022024062A1 (en) 2020-07-30 2022-02-03 Genzyme Corporation Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same
WO2022215083A1 (en) * 2021-04-05 2022-10-13 Msn Laboratories Private Limited, R&D Center Solid state forms of (s)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl) carbamate or salts and process for its preparation thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
JP2002522509A (ja) 1997-10-29 2002-07-23 ジェンザイム・コーポレイション リソソーム貯蔵疾患治療組成物および方法
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
WO2010091104A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
EP3482767B1 (en) 2009-08-28 2021-10-06 Icahn School of Medicine at Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
PT2685986T (pt) * 2011-03-18 2020-03-05 Genzyme Corp Inibidor de glicosilceramida-sintase

Also Published As

Publication number Publication date
JP2016513679A (ja) 2016-05-16
BR112015022907A8 (pt) 2019-11-26
SG11201507054YA (en) 2015-10-29
BR112015022907B1 (pt) 2022-07-12
PH12015502021A1 (en) 2016-01-11
UY35439A (es) 2014-10-31
KR102302064B1 (ko) 2021-09-13
SA515361078B1 (ar) 2018-06-14
EP2970250A1 (en) 2016-01-20
AU2014240028B2 (en) 2018-08-02
HRP20210692T1 (hr) 2021-06-11
PL2970250T3 (pl) 2021-12-06
PT2970250T (pt) 2021-05-07
US20160039805A1 (en) 2016-02-11
TW201502127A (zh) 2015-01-16
TWI713438B (zh) 2020-12-21
HUE054349T2 (hu) 2021-09-28
JP6438455B2 (ja) 2018-12-12
BR112015022907A2 (pt) 2017-07-18
LT2970250T (lt) 2021-05-10
MY181766A (en) 2021-01-06
MX370178B (es) 2019-12-04
ZA201506602B (en) 2023-04-26
ES2872326T3 (es) 2021-11-02
SI2970250T1 (sl) 2021-06-30
US9518049B2 (en) 2016-12-13
NZ712659A (en) 2020-11-27
KR20150132333A (ko) 2015-11-25
RS61852B1 (sr) 2021-06-30
TN2015000427A1 (en) 2017-01-03
AU2014240028A1 (en) 2015-10-15
IL241229A0 (en) 2015-11-30
MX2015012295A (es) 2016-05-16
CL2015002701A1 (es) 2016-03-18
MA38488A1 (fr) 2017-10-31
CA2906691A1 (en) 2014-09-25
EA037527B1 (ru) 2021-04-08
EP2970250B1 (en) 2021-04-21
HK1214821A1 (zh) 2016-08-05
CN105189490A (zh) 2015-12-23
AR095435A1 (es) 2015-10-14
EA201591706A1 (ru) 2016-02-29
IL241229B (en) 2019-12-31
WO2014152215A1 (en) 2014-09-25
DK2970250T3 (da) 2021-07-12

Similar Documents

Publication Publication Date Title
TN2015000091A1 (en) Glucosylceramide synthase inhibitors
UA118248C2 (uk) Інгібітори глюкозилцерамідсинтази
TN2015000427A1 (en) Salt forms of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
SG10201804952QA (en) Glucosylceramide synthase inhibitors
MX2015012842A (es) Prodecimiento para preparar inhibidores de la glucosilceramida sintasa.
MX2016005437A (es) Derivados de n-(1-hidroxi-3-(pirrolidinil)propan-2-il)pirrolidin-3 -carboxamida como inhibidores de glucosilceramida sintasa.
TN2013000368A1 (en) Glucosylceramide synthase inhibitors
PH12020500472A1 (en) Autotaxin inhibitor compounds
TH170238A (th) รูปเกลือของ (s)-ควินิวคลิดิน-3-อิล (2-(2-(4-ฟลูออโรฟีนิล)ไทอาโซล-4-อิล)โพรเพน-2-อิล)คาร์บาเมต